Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial

BACKGROUND: Buprenorphine/naloxone (Suboxone) is a current first-line treatment for opioid use disorder (OUD). The standard induction method of buprenorphine/naloxone requires patients to be abstinent from opioids and therefore experience withdrawal symptoms prior to induction, which can be a barrie...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, James S. H., Nikoo, Mohammadali, Westenberg, Jean N., Suen, Janet G., Wong, Jennifer Y. C., Krausz, Reinhard M., Schütz, Christian G., Vogel, Marc, Sidhu, Jesse A., Moe, Jessica, Arishenkoff, Shane, Griesdale, Donald, Mathew, Nickie, Azar, Pouya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881636/
https://www.ncbi.nlm.nih.gov/pubmed/33579359
http://dx.doi.org/10.1186/s13722-021-00220-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881636/
https://www.ncbi.nlm.nih.gov/pubmed/33579359
http://dx.doi.org/10.1186/s13722-021-00220-2

Ejemplares similares